Back to Journals » Journal of Pain Research » Volume 10

Rational dosing of gabapentin and pregabalin in chronic kidney disease

Authors Raouf M, Atkinson TJ, Crumb MW, Fudin J

Received 22 December 2016

Accepted for publication 10 January 2017

Published 27 January 2017 Volume 2017:10 Pages 275—278

DOI https://doi.org/10.2147/JPR.S130942

Checked for plagiarism Yes

Editor who approved publication: Dr E. Alfonso Romero-Sandoval

Mena Raouf,1 Timothy J Atkinson,1 Meredith W Crumb,1 Jeffrey Fudin2–5

1VA Tennessee Valley Healthcare System, Murfreesboro, Nashville, TN, 2Stratton VA Medical Center, 3Albany College of Pharmacy and Health Sciences, Albany, NY, 4Western New England University College of Pharmacy, Springfield, MA, 5Scientific and Clinical Affairs, Remitigate LLC, Delmar, NY, USA
 
Introduction
Renal dose adjustments for gabapentin and pregabalin are ubiquitously evident in the medical literature. All manufacturers for these branded and generic dosage forms list dosing recommendations relative to creatinine clearance (CrCl) for both medications (Table 1).1,2 However, the basis of these recommendations has not been well articulated. 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]